These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34663921)

  • 21. A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources.
    Xiang H; Zhang L; Bu F; Guan X; Chen L; Zhang H; Zhao Y; Chen H; Zhang W; Li Y; Lee LJ; Mei Z; Rao Y; Gu Y; Hou Y; Mu F; Dong X
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.
    Caron E; Kowalewski DJ; Chiek Koh C; Sturm T; Schuster H; Aebersold R
    Mol Cell Proteomics; 2015 Dec; 14(12):3105-17. PubMed ID: 26628741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
    Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
    J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Game of Omes: ribosome profiling expands the MHC-I immunopeptidome.
    Holly J; Yewdell JW
    Curr Opin Immunol; 2023 Aug; 83():102342. PubMed ID: 37247567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.
    Rozanov DV; Rozanov ND; Chiotti KE; Reddy A; Wilmarth PA; David LL; Cha SW; Woo S; Pevzner P; Bafna V; Burrows GG; Rantala JK; Levin T; Anur P; Johnson-Camacho K; Tabatabaei S; Munson DJ; Bruno TC; Slansky JE; Kappler JW; Hirano N; Boegel S; Fox BA; Egelston C; Simons DL; Jimenez G; Lee PP; Gray JW; Spellman PT
    J Proteomics; 2018 Mar; 176():13-23. PubMed ID: 29331515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
    Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
    Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma.
    Jiang C; Schaafsma E; Hong W; Zhao Y; Zhu K; Chao CC; Cheng C
    Front Immunol; 2021; 12():703821. PubMed ID: 35111147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens.
    Cuevas MVR; Hardy MP; Larouche JD; Apavaloaei A; Kina E; Vincent K; Gendron P; Laverdure JP; Durette C; Thibault P; Lemieux S; Perreault C; Ehx G
    Genome Biol; 2023 Aug; 24(1):188. PubMed ID: 37582761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
    Ghorani E; Rosenthal R; McGranahan N; Reading JL; Lynch M; Peggs KS; Swanton C; Quezada SA
    Ann Oncol; 2018 Jan; 29(1):271-279. PubMed ID: 29361136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
    Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
    Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
    Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and characterization of actionable tumor antigens.
    Ehx G; Perreault C
    Genome Med; 2019 Apr; 11(1):29. PubMed ID: 31039809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MHC-binding peptides as immunotherapeutics for cancer.
    Kobayashi H; Kennedy R; Lu J; Davila E; Celis E
    Immunol Invest; 2000 May; 29(2):105-10. PubMed ID: 10854176
    [No Abstract]   [Full Text] [Related]  

  • 36. IDENTIFICATION OF MHC PEPTIDES USING MASS SPECTROMETRY FOR NEOANTIGEN DISCOVERY AND CANCER VACCINE DEVELOPMENT.
    Chen R; Fulton KM; Twine SM; Li J
    Mass Spectrom Rev; 2021 Mar; 40(2):110-125. PubMed ID: 31875992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
    Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
    Mol Cell Proteomics; 2019 Jun; 18(6):1255-1268. PubMed ID: 31154438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif.
    Gastaldello A; Ramarathinam SH; Bailey A; Owen R; Turner S; Kontouli N; Elliott T; Skipp P; Purcell AW; Siddle HV
    Immunology; 2021 Jun; 163(2):169-184. PubMed ID: 33460454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solving an MHC allele-specific bias in the reported immunopeptidome.
    Klatt MG; Mack KN; Bai Y; Aretz ZEH; Nathan LI; Mun SS; Dao T; Scheinberg DA
    JCI Insight; 2020 Oct; 5(19):. PubMed ID: 32897882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
    Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
    Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.